Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Akiko TSUBOTA"'
Publikováno v:
Journal of Health Economics and Outcomes Research (2021)
**Objectives:** We developed a Markov model to simulate a treatment flow of epilepsy patients who refer to specialized care from non-specialized care, and to surgery from specialized care for estimation of patient distributions and expenditures cause
Externí odkaz:
https://doaj.org/article/874de6296d3d41c8bc995594e9847271
Publikováno v:
Journal of Health Economics and Outcomes Research, Vol 8, Iss 1 (2021)
**Objectives:** We developed a Markov model to simulate a treatment flow of epilepsy patients who refer to specialized care from non-specialized care, and to surgery from specialized care for estimation of patient distributions and expenditures cause
Externí odkaz:
https://doaj.org/article/5136535034b94ccaa8ca9c4451f351cd
Publikováno v:
PLoS ONE, Vol 13, Iss 4, p e0195789 (2018)
BACKGROUND:Limited availability of real-world data that describe treatment patterns of Japanese prostate cancer (PCA) patients. METHODS:A biweekly transition analysis of PCA treatment was performed for patients with PCA diagnosis and a specific treat
Externí odkaz:
https://doaj.org/article/ed1414b6aa4f4f2db2acc2d0f6086bff
Publikováno v:
Asian Journal of Human Services. 23:21-42
Publikováno v:
Journal of Health Economics and Outcomes Research
Journal of Health Economics and Outcomes Research (2021)
Journal of Health Economics and Outcomes Research (2021)
**Objectives:** We developed a Markov model to simulate a treatment flow of epilepsy patients who refer to specialized care from non-specialized care, and to surgery from specialized care for estimation of patient distributions and expenditures cause
Publikováno v:
PharmacoEconomics Open
Background Ibrutinib was introduced in Japan in 2016 as a new oral treatment option for patients with relapsed/refractory (RR) chronic lymphocytic leukemia (CLL). There is increasing interest from the Japanese government to assess economic aspects of
Publikováno v:
Current medical research and opinion. 34(10)
Objective: The objective was to assess the burden of chemotherapy for castration-resistant prostate cancer (CRPC) in Japan. Methods: Utilizing a large administrative hospital database we compared a set of outcome measures 12 months before and after i
Publikováno v:
PLoS ONE, Vol 13, Iss 4, p e0195789 (2018)
PLoS ONE
PLoS ONE
Background Limited availability of real-world data that describe treatment patterns of Japanese prostate cancer (PCA) patients. Methods A biweekly transition analysis of PCA treatment was performed for patients with PCA diagnosis and a specific treat
Autor:
Tamio Suzuki, Takuro Kanekura, Yuko Abe, Ken Okamura, Akiko Tsubota, Hironori Niizeki, Yasutsugu Chinen, Takayuki Konno, Yuta Araki, Akari Shigyou, Toshiharu Fujiyama, Yutaka Hozumi, Atsunori Baba, Michihiro Kono
Publikováno v:
Journal of dermatological science. 81(2)
Publikováno v:
Skin Cancer. 21:184-188